Monthly research recap
Psychedelic-assisted therapy research: September 2026
What September 2026's 8 new studies found, synthesized from the papers below. All Psychedelic-assisted therapy research →
The synthesis
Synthesized from 8 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psychedelic-assisted therapy, psychedelic therapy, assisted psychotherapy, psychedelic-assisted psychotherapy, then ranked by relevance.
Research indexed in September 2026 on psychedelic-assisted therapy reports mostly positive but preliminary signals: small clinical series and secondary trial analyses show reductions in depression, anxiety and suicidal ideation, and reviews describe clinically meaningful effects in depression and substance use. However, the evidence base is limited by very small samples, heterogeneity between individuals, and largely correlational mechanism data. A review of older controlled trials and a meta-research review raise concerns about durability of benefit and inconsistent risk-of-bias judgments across evidence syntheses.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| A longitudinal analysis of the clinical practice of ketamine assisted psychotherapy with adolescents and young adults 2026 | observational cohort (longitudinal clinical case series) | 19 | Supports | Depression scores declined by an estimated 0.65 points per visit and anxiety scores by 0.21 points per visit, with medium or large individual treatment effects in about 63% of cases for depression and 47% for anxiety, and overall benefit reported in 68% of cases; ketamine was well tolerated across 167 sessions. |
| Exploratory safety, tolerability, and feasibility of psilocybin-assisted psychotherapy for adults with co-occurring treatment-resistant depression and cluster B personality disorders 2026 | secondary analysis of a clinical trial | 10 | Supports | Mean depression scores fell from 30.4 pre-treatment to 22.3 at six months and the mean suicidal ideation item fell from 3.2 to 1.2, with substantial heterogeneity between individuals and no serious adverse events. |
| Comparative Policy Analysis of Psychedelic Therapy Regulation in Australia, Brazil, and the USA 2026 | review | Unclear | Argues that psychedelic regulation across Australia, Brazil and the USA is shaped by cultural acceptance, healthcare infrastructure, indigenous traditions and political priorities, with Australia having the most organized therapeutic access route and the USA largely retaining Schedule 1 classification. | |
| Open research data for: Limits of evidence-synthesis in psychedelic-assisted psychotherapy: a meta-research study of systematic reviews, meta-analyses and randomized trials 2026 | meta-research data descriptor | Unclear | Describes open research data comprising extraction, coding, identity mappings and appraisals produced for a meta-research study of systematic reviews, meta-analyses and randomized trials in psychedelic-assisted psychotherapy. | |
| 846. Inconsistent trial risk-of-bias judgements across psychedelic-assisted psychotherapy systematic reviews 2026 | systematic review | 17 | Opposes | Risk of bias was assessed in 14 of 17 reviews but only 2 of 14 provided supporting comments, and among 48 MDMA trial-by-domain comparisons with at least two ratings, 22 were discordant, indicating an under-recognized methodological vulnerability in evidence syntheses. |
| 252. Clinical application of psychedelic-assisted therapy in major depression and addictions 2026 | review | Supports | Argues that psychedelic compounds can transiently reduce brain network rigidity and enhance plasticity, and reports significant depressive symptom reductions in trials with promising early signals for substance use and eating disorders, while noting variability in sample sizes and follow-up durations. | |
| Psychedelic therapy without durable effects: A review and re-evaluation of controlled studies between 1965 and 1977. 2026 | review | 11 | Opposes | Argues that early controlled psychedelic trials were methodologically sound for their era and that most found no durable patient improvements beyond a few weeks, with implications for patient selection, mechanisms and the need for strong psychotherapeutic frameworks. |
| Through the Looking-Glass: A Scoping Review of Psychological Mechanisms of Psychedelic-Assisted Therapy for Substance Use Disorders 2026 | scoping review | 1003 | Mixed | Identified six transdiagnostic mechanism domains across 37 publications representing 23 cohorts, with mystical-type experiences most frequently examined and associated with reductions in substance use and craving, but evidence is largely correlational and only one randomized trial demonstrated mediation. |
Points of agreement
- Small clinical studies and reviews report reductions in depressive symptoms, anxiety and suicidal ideation after psychedelic-assisted therapy.
- Benefit is described as promising but preliminary, with substantial heterogeneity between individuals.
- Mechanistic explanations center on increased neural and psychological flexibility and on mystical-type experiences.
- Safety and tolerability are generally described as acceptable in the clinical samples studied.
Conflicts
- A review of early controlled trials argues there were no durable improvements beyond a few weeks, contrasting with the positive symptom reductions reported in recent small trials and reviews.
- A meta-research review finds inconsistent risk-of-bias judgments across systematic reviews, undermining confidence in the synthesized evidence base.
- Mechanism evidence is largely correlational, with only one randomized trial demonstrating mediation, which limits causal claims.
Gaps
- Durability of benefit beyond a few weeks or months is not established.
- Sample sizes are very small, limiting generalizability.
- Blinding and active control conditions remain problematic in contemporary trials.
- Long-term safety and adverse event data are limited.
- Populations studied are narrow, including adolescents and young adults in one clinic, comorbid personality disorders, and substance use disorders.
- Dose and dosing paradigms are not well characterized across studies.